| Literature DB >> 25514152 |
Astrid M Knoblauch1, Mary H Hodges2, Mohamed S Bah3, Habib I Kamara4, Anita Kargbo5, Jusufu Paye6, Hamid Turay7, Emmanuel D Nyorkor8, Mark J Divall9, Yaobi Zhang10, Jürg Utzinger11, Mirko S Winkler12.
Abstract
Large private sector investments in low- and middle-income countries are often critically evaluated with regards to their environmental, social, human rights, and health impacts. A health impact assessment, including a baseline health survey, was commissioned by the Addax Bioenergy Sierra Leone project in 2010. As part of the monitoring, a follow-up survey was conducted three years later. A set of health indicators was assessed at six impacted and two control sites. Most of these indices improved, particularly at the impacted sites. The prevalences of stunting, wasting, and Plasmodium falciparum in children under five years of age decreased significantly at impacted sites (all p < 0.05) and non-significantly at control sites. Anemia in children and in women of reproductive age (15-49 years) decreased significantly at impacted and control sites (p < 0.05 and p < 0.001, respectively). Health facility-based deliveries increased significantly at the impacted sites (p < 0.05). The prevalences of helminth infections in children aged 10-15 years remained approximately at the same levels, although focal increases at the impacted sites were noted. Access to improved sanitation decreased significantly (p < 0.05) at control and non-significantly at impacted sites. Water quality remained poor without significant changes. The epidemiologic monitoring of a bioenergy project provides a useful contribution for evidence-based decision-making.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25514152 PMCID: PMC4276658 DOI: 10.3390/ijerph111212997
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1National interventions or programs and interventions initiated by the Addax Bioenergy Sierra Leone (ABSL) project between 2010 and 2013 and the associated health impacts.
Figure 2Sentinel sites of the follow-up health survey in the ABSL project study area in Northern Sierra Leone, 2013.
Figure 3Participation and adherence in the different survey arms of the three-year follow-up health survey in the ABSL project study area, 2013.
Sample sizes at the impacted and the control sentinel sites, in the ABSL project study area, 2010 and 2013.
| Characteristics | Impacted Sentinel Sites | Control Sentinel Sites | ||
|---|---|---|---|---|
| 2010 | 2013 | 2010 | 2013 | |
| Sentinel sites | 6 | 6 | 2 | 2 |
| Households | 143 | 137 | 51 | 50 |
| Children aged <59 months | 421 | 390 | 164 | 214 |
| Children aged 6–59 months | 409 | 350 | 161 | 199 |
| School-going children aged 10–15 years | 180 | 181 | 60 | 60 |
| Women aged 15–49 years | 284 | 255 | 113 | 122 |
| Non-pregnant | 234 | 230 | 97 | 107 |
| Pregnant | 50 | 25 | 16 | 15 |
Key health indicators at the impacted and the control sentinel sites, in the ABSL project study area, 2010 and 2013.
| Impacted Sentinel Sites | Control Sentinel Sites | ||||
|---|---|---|---|---|---|
| 2010 | 2013 | 2010 | 2013 | ||
| Individuals | 421 | 390 | 164 | 214 | |
| Households | 149 | 131 | 52 | 50 | |
| Sentinel sites | 6 | 6 | 2 | 2 | |
| Mean/sentinel site (range) | 68 (24–99) | 58 (21–91) | 81 (75–86) | 100 (83–116) | |
| Prevalence (95% CI) | 5.7 (3.4–8.0) | 2.8 (1.0–4.6) | 4.3 (0.9–7.7) | 4.2 (1.3–7.1) | |
| Range | 0.0–9.2 | 0.0–6.8 | 3.4–5.3 | 3.3–5.5 | |
| 0.044 | 0.976 | ||||
| Prevalence (95% CI) | 41.8 (37.0–46.6) | 32.1 (27.3–36.8) | 42.1 (34.2–49.9) | 40.7 (33.8–47.5) | |
| Range | 35.3–48.5 | 18.2–39.6 | 37.5–47.4 | 37.4–45.1 | |
| 0.004 | 0.781 | ||||
| Prevalence (95% CI) | 23.0 (18.9–27.2) | 13.3 (9.8–16.8) | 25.0 (18.1–31.9) | 15.0 (9.9–20.0) | |
| Range | 13.6–27.7 | 8.5–19.3 | 22.4–27.3 | 14.3–15.4 | |
| <0.001 | 0.014 | ||||
| Individuals | 409 | 350 | 161 | 199 | |
| Households | 149 | 131 | 52 | 50 | |
| Sentinel sites | 6 | 6 | 2 | 2 | |
| Mean/sentinel site (range) | 68 (24–99) | 58 (21–91) | 81 (75–86) | 100 (83–116) | |
| Prevalence (95% CI) | 73.8 (68.6–78.5) | 62.5 (56.4–68.2) | 76.0 (67.4–83.0) | 72.8 (66.5–78.3) | |
| Range | 37.3–96.2 | 55.5–79.7 | 59.3–94.7 | 70.3–75.8 | |
| 0.001 | 0.530 | ||||
| Prevalence (95% CI) | 85.8 (82.0–88.8) | 80.0 (75.3–84.0) | 87.5 (80.9–92.0) | 75.9 (69.5–81.3) | |
| Range | 67.9–92.6 | 67.3–89.0 | 82.4–93.5 | 68.9–85.6 | |
| 0.033 | 0.005 | ||||
| Prevalence (95% CI) | 94.6 (90.9–96.8) | 55.1 (47.0–63.0) | 96.8 (88.0–99.2) | 67.1 (53.9–78.1) | |
| Range | 83.8–100.0 | 45.8–60.2 | 93.9–100.0 | 44.8–88.8 | |
| <0.001 | <0.001 | ||||
| Individuals | 180 | 181 | 60 | 60 | |
| Sentinel sites | 6 | 6 | 2 | 2 | |
| Mean/sentinel site (range) | 30 (30–30) | 30 (30–30) | 30 (30–30) | 30 (30–30) | |
| Prevalence (95% CI) | 1.7 (0.0–3.6) | 3.9 (1.0–6.7) | 5.0 (0.0–10.7) | 8.3 (1.1–15.5) | |
| Range | 0.0–3.3 | 0.0–13.3 | 3.3–6.7 | 6.7–10.0 | |
| 0.203 | 0.464 | ||||
| Prevalence (95% CI) | 1.1 (0.0–2.7) | 11.1 (6.4–15.6) | 1.7 (0.0–5.0) | 1.7 (0.0–5.0) | |
| Range | 0.0–3.3 | 3.3–40.0 | 0.0–3.3 | 0.0–3.3 | |
| <0.001 | 1.000 | ||||
| Prevalence (95% CI) | 23.9 (17.6–30.2) | 28.7 (22.1–35.4) | 40.0 (27.2–52.8) | 41.7 (28.8–54.5) | |
| Range | 3.3–50.0 | 10.0–63.3 | 33.3–46.7 | 36.7–46.7 | |
| 0.296 | 0.853 | ||||
| Prevalence (95% CI) | 2.2 (0.1–4.4) | 1.1 (0.0–2.6) | 1.7 (0.0–5.0) | 0.0 (0.0–0.0) | |
| Range | 0.0–3.3 | 0.0–6.7 | 0.0–3.3 | 0.0–0.0 | |
| 0.406 | 0.315 | ||||
| Individuals | 284 | 255 | 113 | 122 | |
| Sentinel sites | 6 | 6 | 2 | 2 | |
| Mean/sentinel site (range) | 47 (20–76) | 43 (21–58) | 57 (52–61) | 61 (58–64) | |
| Prevalence (95% CI) | 72.8 (67.2–77.8) | 40.5 (34.4–46.8) | 75.9 (68.4–82.0) | 33.4 (25.5–42.5) | |
| Range | 53.8–84.0 | 30.4–48.0 | 70.2–80.3 | 22.3–43.6 | |
| <0.001 | <0.001 | ||||
Figure 4Indicators in children under five years of age in the ABSL study area, stratified by sentinel site, 2010 and 2013. (A) Prevalence of wasting (<−2 SD) in children aged <59 months; (B) prevalence of stunting (<−2 SD) in children aged <59 months; (C) prevalence of being underweight (<−2 SD) in children aged <59 months; (D) prevalence of anemia in children aged 6–59 months; (E) prevalence of Plasmodium falciparum in children aged 6–59 months; and (F) insecticide treated net use in the night preceding the survey in children aged 6–59 months.
Figure 5Indicators in women of reproductive age (15–49 years) and school-going children aged 10–15 years in the ABSL study area, stratified by sentinel site, 2010 and 2013. (A) Prevalence of anemia in women aged 15–49 years (Hb < 11 g/dL in pregnant women; Hb < 12 g/dL in non-pregnant women); (B) proportion of women aged 15–49 years who delivered the last child at a health facility; (C) proportion of women aged 15–49 years reporting that their household has an improved sanitation facility; (D) prevalence of S. mansoni in children aged 10–15 years; (E) prevalence of A. lumbricoides in children aged 10–15 years; and (F) prevalence of hookworm in children aged 10–15 years.
Percentage of mothers giving birth at a health facility and the percentage of households having access to safe sanitation, in the ABSL study area, 2010 and 2013.
| Impacted Sentinel Sites | Control Sentinel Sites | ||||
|---|---|---|---|---|---|
| 2010 | 2013 | 2010 | 2013 | ||
| Individuals/households | 144 | 137 | 51 | 50 | |
| Sentinel sites | 6 | 6 | 2 | 2 | |
| Mean/sentinel site (range) | 24 (15–26) | 23 (17–27) | 25 (25–26) | 25 (25–25) | |
| Prevalence (95% CI) | 63.2 (54.8–71.1) | 81.0 (73.4–87.2) | 66.7 (52.1–79.2) | 68.0 (53.3–80.5) | |
| Range | 26.9–91.7 | 47.1–100.0 | 34.6–100.0 | 48.0–88.0 | |
| <0.001 | 0.886 | ||||
| Prevalence (95% CI) | 19.4 (13.3–26.9) | 18.3 (12.2–25.7) | 39.2 (25.8–53.9) | 18.0 (8.6–31.4) | |
| Range | 0.0–33.3 | 0.0–37.0 | 34.6–44.0 | 4.0–32.0 | |
| 0.798 | 0.019 | ||||
Percentage of drinking water samples at the household and source level positive for coliform, in the ABSL study area, 2010 and 2013.
| Impacted Sentinel Sites | Control Sentinel Sites | ||||
|---|---|---|---|---|---|
| 2010 | 2013 | 2010 | 2013 | ||
| Households | 72 | 60 | 24 | 20 | |
| Sources | 18 | 16 | 6 | 9 | |
| Sentinel sites | 6 | 6 | 2 | 2 | |
| Prevalence (95% CI) | 98.6 (92.5–99.9) | 100.0 (83.2–100.0) | 95.8 (78.9–99.9) | 100.0 (94.0–100.0) | |
| Range | 91.7–100.0 | 100.0–100.0 | 91.7–100.0 | 100.0–100.0 | |
| 0.359 | 0.356 | ||||
| Prevalence (95% CI) | 94.4 (72.7–99.9) | 87.5 (61.7–98.4) | 83.3 (35.9–99.6) | 88.9 (51.8–99.7) | |
| Range | 50.0–100.0 | 66.7–100.0 | 75.0–100.0 | 75.0–100.0 | |
| 0.476 | 0.756 | ||||